Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
66 studies found for:    Elvitegravir OR Elvitegravir[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
21 Recruiting Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
Condition: HIV-1 Infection
Intervention: Drug: E/C/F/TAF
22 Completed
Has Results
Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
Condition: HIV Infections
Interventions: Drug: EVG;   Drug: RTV;   Drug: ARV regimen
23 Completed
Has Results
Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
Condition: HIV
Intervention: Drug: (FDC) ELV/COBI/FTC/TDF
24 Completed Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study
Conditions: Hepatitis C Infection;   HIV Infection
Intervention: Drug: Sofosbuvir, Ribavirin, and Stribild
25 Not yet recruiting A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
Condition: HIV Infections
Interventions: Drug: ELV/COBI/FTC/TAF;   Drug: DTG/3TC/ABC + ELV/COBI/FTC/TAF
26 Recruiting Early ART to Limit Infection and Establishment of Reservoir
Condition: HIV-1 Infection
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
27 Active, not recruiting
Has Results
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: E/C/F/TDF Placebo;   Drug: E/C/F/TAF Placebo
28 Active, not recruiting
Has Results
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: E/C/F/TDF Placebo;   Drug: E/C/F/TAF Placebo
29 Completed Atripla to Stribild Switch Study to Evaluate Sleep Disturbances
Conditions: HIV;   AIDS;   Sleep Disorders
Intervention: Drug: elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil
30 Active, not recruiting
Has Results
Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TDF;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: E/C/F/TDF Placebo;   Drug: RTV Placebo;   Drug: ATV Placebo;   Drug: FTC/TDF Placebo;   Drug: E/C/F/TAF
31 Completed
Has Results
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: Atripla;   Drug: Stribild Placebo;   Drug: Atripla Placebo
32 Active, not recruiting Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
Conditions: HIV-1 Infection;   HCV Infection
Interventions: Drug: E/C/F/TAF;   Drug: F/R/TAF;   Drug: LDV/SOF
33 Completed
Has Results
Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TDF;   Drug: E/C/F/TAF Placebo;   Drug: E/C/F/TAF;   Drug: E/C/F/TDF Placebo
34 Completed
Has Results
Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: Atripla
35 Active, not recruiting HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
Conditions: Human Immunodeficiency Virus;   Hepatitis C, Chronic
Interventions: Drug: E/C/F/TAF;;   Drug: Ledipasvir-Sofosbuvir
36 Completed HIV Non-Occupational Post-Exposure Prophylaxis
Condition: Human Immunodeficiency Virus
Intervention: Drug: Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
37 Completed
Has Results
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: Stribild;   Drug: ATV;   Drug: Ritonavir;   Drug: FTC/TDF;   Drug: Stribild Placebo;   Drug: ATV Placebo;   Drug: RTV Placebo;   Drug: FTC/TDF Placebo
38 Active, not recruiting Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents
Condition: HIV
Intervention: Drug: E/C/F/TAF
39 Active, not recruiting
Has Results
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Conditions: HIV;   HIV Infections
Intervention: Drug: E/C/F/TAF
40 Completed
Has Results
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
Conditions: HIV;   HBV
Intervention: Drug: E/C/F/TAF

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.